Abbott Finalizes Multi-Billion Dollar Acquisition of Exact Sciences
雅培完成對 Exact Sciences 數十億美元的收購案
On March 23, 2026, the medical giant Abbott officially finalized its multi-billion dollar acquisition of Exact Sciences, a strategic move valued at approximately $23 billion.
2026年3月23日，醫療巨頭亞培（Abbott）正式完成對Exact Sciences價值約230億美元的數十億美元併購案。
This merger is set to position Abbott as a powerhouse in the growing fields of cancer screening and precision oncology.
此項併購將使亞培在日益成長的癌症篩檢與精準腫瘤學領域中佔據強勢地位。
As part of the agreement, Exact Sciences will function as a subsidiary while maintaining its home base in Madison, Wisconsin.
根據協議，Exact Sciences將成為子公司，並繼續維持其位於威斯康辛州麥迪遜的總部。
This acquisition allows Abbott to incorporate a prestigious product portfolio, including the well-known Cologuard for colorectal cancer screening and the Oncotype DX test for breast cancer treatment planning.
此項收購使亞培能納入一系列享負盛名的產品組合，包括廣為人知的結直腸癌篩檢產品Cologuard，以及用於乳癌治療規劃的Oncotype DX測試。
Industry experts note that this expansion will add roughly $3 billion to Abbott's annual sales.
產業專家指出，此擴張將為亞培每年增加約30億美元的銷售額。
CEO Robert B.
執行長Robert B.
Ford emphasized that this transition represents a pivotal shift toward more predictive and personalized diagnostic healthcare.
Ford強調，此轉變代表向更具預測性與個人化的診斷醫療邁出了關鍵的一步。
By combining Exact Sciences' innovative technology with Abbott's massive global commercial network, the company aims to broaden international access to life-saving cancer tests.
透過將Exact Sciences的創新技術與亞培龐大的全球商業網絡相結合，該公司旨在擴大國際間對救命癌症測試的獲取管道。
While Kevin Conroy, the CEO of Exact Sciences, transitions into an advisory role, the industry watches closely to see how this deal will reshape the future of diagnostic medicine on a global scale.
當Exact Sciences的執行長Kevin Conroy轉任顧問職務時，業界正密切關注這項協議將如何在全球範圍內重塑診斷醫學的未來。
